Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$337.42 +1.8%	$346.62	$267.83 ▼ $391.29	$182.10B	0.44	2.75 million shs	1.93 million shs
BIIB Biogen	$189.47 +0.9%	$185.39	$121.05 ▼ $205.97	$27.97B	0.19	1.30 million shs	1.47 million shs
MRK Merck & Co., Inc.	$115.86 +2.5%	$115.82	$75.40 ▼ $125.14	$286.15B	0.18	10.83 million shs	7.28 million shs
MRNA Moderna	$47.26 -1.8%	$51.16	$22.28 ▼ $59.55	$18.75B	1.05	9.61 million shs	4.76 million shs
PFE Pfizer	$25.93 +0.5%	$26.91	$22.81 ▼ $28.75	$147.76B	0.35	42.00 million shs	20.15 million shs

The 10 Best AI Stocks to Own in 2026

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+0.25%	-1.45%	-5.31%	-11.70%	+20.57%
BIIB Biogen	-1.45%	-8.18%	+2.43%	-2.23%	+43.85%
MRK Merck & Co., Inc.	-1.07%	-0.49%	-3.53%	-7.24%	+45.04%
MRNA Moderna	+5.25%	-4.56%	-11.85%	-3.18%	+71.92%
PFE Pfizer	+0.44%	-0.69%	-6.41%	-4.07%	+9.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$337.42 +1.8%	$346.62	$267.83 ▼ $391.29	$182.10B	0.44	2.75 million shs	1.93 million shs
BIIB Biogen	$189.47 +0.9%	$185.39	$121.05 ▼ $205.97	$27.97B	0.19	1.30 million shs	1.47 million shs
MRK Merck & Co., Inc.	$115.86 +2.5%	$115.82	$75.40 ▼ $125.14	$286.15B	0.18	10.83 million shs	7.28 million shs
MRNA Moderna	$47.26 -1.8%	$51.16	$22.28 ▼ $59.55	$18.75B	1.05	9.61 million shs	4.76 million shs
PFE Pfizer	$25.93 +0.5%	$26.91	$22.81 ▼ $28.75	$147.76B	0.35	42.00 million shs	20.15 million shs

The 10 Best AI Stocks to Own in 2026

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+0.25%	-1.45%	-5.31%	-11.70%	+20.57%
BIIB Biogen	-1.45%	-8.18%	+2.43%	-2.23%	+43.85%
MRK Merck & Co., Inc.	-1.07%	-0.49%	-3.53%	-7.24%	+45.04%
MRNA Moderna	+5.25%	-4.56%	-11.85%	-3.18%	+71.92%
PFE Pfizer	+0.44%	-0.69%	-6.41%	-4.07%	+9.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.48	Hold	$355.19	5.27% Upside
BIIB Biogen	2.52	Moderate Buy	$215.62	13.80% Upside
MRK Merck & Co., Inc.	2.68	Moderate Buy	$128.18	10.63% Upside
MRNA Moderna	1.84	Reduce	$35.73	-24.39% Downside
PFE Pfizer	2.19	Hold	$28.61	10.36% Upside

Current Analyst Ratings Breakdown

Latest MRNA, MRK, BIIB, PFE, and AMGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2026	AMGN Amgen	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$400.00 ➝ $375.00
5/15/2026	MRK Merck & Co., Inc.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
5/15/2026	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$214.00 ➝ $225.00
5/15/2026	BIIB Biogen	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
5/14/2026	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/14/2026	PFE Pfizer	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underperform	$26.00
5/14/2026	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$432.00 ➝ $427.00
5/14/2026	BIIB Biogen	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$275.00 ➝ $300.00
5/13/2026	AMGN Amgen	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$410.00 ➝ $390.00
5/7/2026	AMGN Amgen	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/6/2026	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)

(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$36.75B	4.95	$34.50 per share	9.78	$17.03 per share	19.81
BIIB Biogen	$9.89B	2.83	$22.50 per share	8.42	$126.33 per share	1.50
MRK Merck & Co., Inc.	$65.01B	4.40	$11.59 per share	10.00	$18.60 per share	6.23
MRNA Moderna	$1.94B	9.65	N/A	N/A	$18.67 per share	2.53
PFE Pfizer	$62.58B	2.36	$4.44 per share	5.84	$15.86 per share	1.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$7.71B	$14.37	23.48	14.32	3.32	20.96%	137.41%	13.28%	8/4/2026 (Estimated)
BIIB Biogen	$1.29B	$9.32	20.33	11.44	1.68	13.81%	12.83%	8.01%	7/30/2026 (Estimated)
MRK Merck & Co., Inc.	$18.25B	$3.55	32.64	11.85	2.57	13.59%	27.55%	10.73%	8/4/2026 (Estimated)
MRNA Moderna	-$2.82B	-$8.15	N/A	N/A	N/A	-143.55%	-26.64%	-19.32%	7/31/2026 (Estimated)
PFE Pfizer	$7.77B	$1.31	19.79	9.06	N/A	11.83%	19.44%	8.41%	8/4/2026 (Estimated)

Latest MRNA, MRK, BIIB, PFE, and AMGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
5/1/2026	Q1 2026	MRNA Moderna	-$3.02	-$3.40	-$0.38	-$3.40	$236.37 million	$389.00 million
4/30/2026	Q1 2026	AMGN Amgen	$4.77	$5.15	+$0.38	$3.34	$8.58 billion	$8.62 billion
4/30/2026	Q1 2026	MRK Merck & Co., Inc.	-$1.47	-$1.28	+$0.19	-$1.72	$15.85 billion	$16.29 billion
4/29/2026	Q1 2026	BIIB Biogen	$2.95	$3.57	+$0.62	$2.15	$2.29 billion	$2.48 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$10.08	2.99%	+8.27%	70.15%	14 Years
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
MRK Merck & Co., Inc.	$3.40	2.93%	+5.75%	95.77%	14 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.63%	-13.20%	131.30%	16 Years

Latest MRNA, MRK, BIIB, PFE, and AMGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2026	PFE Pfizer	quarterly	$0.43	6.71%	5/8/2026	5/8/2026	6/12/2026
3/4/2026	AMGN Amgen	quarterly	$2.52	3.09%	5/15/2026	5/15/2026	6/5/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	5.65	1.26	1.01
BIIB Biogen	0.34	3.06	2.41
MRK Merck & Co., Inc.	1.02	1.30	1.06
MRNA Moderna	0.08	2.41	2.35
PFE Pfizer	0.67	1.25	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BIIB Biogen	87.93%
MRK Merck & Co., Inc.	76.07%
MRNA Moderna	75.33%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.85%
BIIB Biogen	0.25%
MRK Merck & Co., Inc.	0.17%
MRNA Moderna	10.80%
PFE Pfizer	0.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	31,500	539.68 million	535.10 million	Optionable
BIIB Biogen	7,500	147.64 million	147.27 million	Optionable
MRK Merck & Co., Inc.	75,000	2.47 billion	2.47 billion	Optionable
MRNA Moderna	4,700	396.79 million	353.93 million	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable

MRNA, MRK, BIIB, PFE, and AMGN Headlines

Recent News About These Companies

ISG Event to Explore How Enterprises Are Delivering Strategic Value From AI

3 hours ago | finance.yahoo.com

Pfizer (PFE) Valuation Check After HYMPAVZI Expansion And Positive Pneumococcal Vaccine Data

3 hours ago | finance.yahoo.com

Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story

May 21 at 7:43 AM | finance.yahoo.com

Pfizer’s Broader Pneumococcal Vaccine Push Might Change The Case For Investing In Pfizer (PFE)

May 21 at 7:43 AM | finance.yahoo.com

The Most Undervalued Healthcare Stock in the S&P 500 Right Now

May 21 at 7:43 AM | fool.com

Laryngeal Cancer Market Research Report 2026-2036, Competitive Analysis of Major Players - Merck & Co., Pfizer, Novartis, and AbbVie

May 21 at 7:43 AM | finance.yahoo.com

PNC Financial Services Group Inc. Sells 241,073 Shares of Pfizer Inc. $PFE

May 21 at 5:33 AM | marketbeat.com

ProShare Advisors LLC Increases Stock Holdings in Pfizer Inc. $PFE

May 21 at 5:04 AM | marketbeat.com

HighTower Advisors LLC Sells 133,130 Shares of Pfizer Inc. $PFE

May 21 at 4:55 AM | marketbeat.com

Pfizer Inc. $PFE Stake Lessened by Callahan Advisors LLC

May 21 at 3:26 AM | marketbeat.com

Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion

May 20 at 3:19 PM | finance.yahoo.com

Pfizer Advances Pneumonia Vaccine After 15-Fold Antibody Response Data

May 20 at 3:19 PM | finance.yahoo.com

FQ1 Healthcare Dividend Roundup: Johnson & Johnson Keeps Outshining Pfizer

May 20 at 1:01 PM | seekingalpha.com

Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion

May 20 at 11:46 AM | zacks.com

Pfizer begins late-stage trial for new pneumococcal shot in infants after strong phase 2 data

May 20 at 10:19 AM | msn.com

How S&P Drug Titan Pfizer Plans To Outdo Its Own $6 Billion Franchise

May 20 at 10:10 AM | investors.com

Pfizer Expands Pneumococcal Vaccine Push With New Programs

May 20 at 9:30 AM | benzinga.com

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

May 20 at 9:00 AM | businesswire.com

Pfizer Inc. $PFE Shares Acquired by Marble Harbor Investment Counsel LLC

May 20 at 5:50 AM | marketbeat.com

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

May 20 at 5:08 AM | reuters.com

How S&P Drug Titan Pfizer Plans To Outdo Its Own $6 Billion Franchise

May 20 at 5:05 AM | investors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRNA, MRK, BIIB, PFE, and AMGN Company Descriptions

Amgen NASDAQ:AMGN

$337.42 +5.85 (+1.76%)

Closing price 04:00 PM Eastern

Extended Trading

$337.44 +0.02 (+0.01%)

As of 04:24 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen NASDAQ:BIIB

$189.47 +1.67 (+0.89%)

Closing price 04:00 PM Eastern

Extended Trading

$190.00 +0.53 (+0.28%)

As of 04:35 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Merck & Co., Inc. NYSE:MRK

$115.86 +2.86 (+2.53%)

Closing price 03:59 PM Eastern

Extended Trading

$115.05 -0.81 (-0.70%)

As of 04:36 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Moderna NASDAQ:MRNA

$47.26 -0.86 (-1.79%)

Closing price 04:00 PM Eastern

Extended Trading

$47.44 +0.19 (+0.39%)

As of 04:36 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer NYSE:PFE

$25.92 +0.14 (+0.52%)

Closing price 03:59 PM Eastern

Extended Trading

$25.89 -0.04 (-0.15%)

As of 04:38 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MRNA, MRK, BIIB, PFE, and AMGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MRNA, MRK, BIIB, PFE, and AMGN Earnings

Compare Dividends

Latest MRNA, MRK, BIIB, PFE, and AMGN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MRNA, MRK, BIIB, PFE, and AMGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRNA, MRK, BIIB, PFE, and AMGN Company Descriptions

Amgen NASDAQ:AMGN

Biogen NASDAQ:BIIB

Merck & Co., Inc. NYSE:MRK

Moderna NASDAQ:MRNA

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools